logo
welcome
Reuters

Reuters

Regeneron beats quarterly results on strong demand for eczema, eye treatments

Reuters
Summary
Nutrition label

81% Informative

Regeneron Pharmaceuticals exceeded estimates for second-quarter revenue and profit.

U.S. sales of Eylea , jointly developed with Bayer AG , rose 2% to $1.53 billion in the reported quarter from a year earlier .

Regeneron 's anti-inflammatory drug, Dupixent , posted quarterly sales of $3.56 billion .

VR Score

92

Informative language

99

Neutral language

72

Article tone

formal

Language

English

Language complexity

56

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links